Advanced image guidance more precisely targets sarcomas, reduces long-term side effects
the ONA take:
Image-guided radiotherapy can effectively treat soft tissue sarcomas in the extremities, significantly reducing long-term side effects without effecting survival rates, according to RTOG 0630, a multi-year, multi-institution phase 2 clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology.
For this study, more than 100 patients with extremity-based soft tissue sarcomas (STS) received pretreatment radiation therapy that used advanced imaging technology to target a substantially smaller area than typically targeted in treating this type of cancer.
A series of daily presurgery images of the tumor were digitally integrated with previous scans to plan a custom-tailored radiation dose that minimized exposure to adjacent healthy tissue.
Assessments 2 years later showed that long-term side effects were 10.5%. Results from a previous study in which patients received radiation to a larger area showed long-term side effects of 37%.
“Although radiation oncology is a technologically intense discipline, wisdom in using these technologies is essential for optimal outcomes,” commented the lead author of the paper.
Image-guided radiotherapy can effectively treat soft tissue sarcomas in the extremities.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|